XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
Want to see TSE:XRTX full AI Analyst Report?
XRTX Stock Chart & Stats
C$0.78
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.78
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$2.43 - C$9.85
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$5.43M
Enterprise Value-C$340.09K
Total Cash (Recent Filing)C$1.19M
Total Debt (Recent Filing)C$51.11K
Price to Earnings (P/E)―
Beta0.34
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding1,392,444
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.28
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtVery low debt reduces solvency and interest-service risk, giving management structural financial flexibility to prioritize R&D and clinical programs. This lowers the probability of forced distress financing over the next several quarters and preserves strategic optionality for partnerships.
Narrowing Operating LossesA consistent reduction in operating losses demonstrates improving cost discipline and a smaller ongoing funding gap. That trend can materially extend runway, lower near-term financing needs, and make the company a more credible partner or acquisition target during continued clinical development.
Focused Clinical-stage Pipeline On Renal Uric-acid TherapiesA concentrated pipeline targeting hyperuricemia-related kidney disease provides clear strategic focus and scientific specialization. This niche focus can create competitive differentiation, concentrate R&D resources efficiently, and enhance partnering or licensing prospects with larger renal-focused biopharma players.
Bears Say
No RevenueAbsence of any revenue means the company remains entirely pre-commercial and dependent on external capital. Without product sales, the firm cannot self-fund development, making long-term viability contingent on successful trials or consistent financing, elevating execution and funding risk.
Ongoing Negative Cash Flow / Cash BurnSustained negative operating and free cash flow forces recurring capital raises or partnerships. Even with improvement, continued burn constrains investment in trials and increases dilution risk or deal dependency, limiting strategic independence over the medium term.
Material Equity ErosionA sharply reduced equity base weakens the balance sheet buffer against trial setbacks or unexpected costs. It heightens funding pressure, can increase cost of capital, and reduces the firm's ability to absorb adverse outcomes without dilutive financing or unfavorable partnership terms.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$2.42 and its highest was C$9.85 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$5.43M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is May 14, 2026 which is in 17 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -C$0.342 earnings per share for the quarter, beating the consensus estimate of -C$1.141 by C$0.799.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.342 in its last earnings report, beating expectations of -C$1.141. Following the earnings report the stock price went down -20.288%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---